What does DANAHER CORP /DE/ (DHR) do?

DANAHER CORP /DE/ (DHR) is a publicly traded company in the Healthcare sector.

What sector does DHR operate in?

DANAHER CORP /DE/ operates in the Healthcare, specifically within the Diagnostics & Research industry. AlphaOS tracks cycle stage, supply-chain relationships, and investment intelligence for companies across all sectors.

Where can I find DHR earnings analysis?

AlphaOS publishes an earnings intelligence page for DANAHER CORP /DE/ (DHR) covering results, guidance context, and AI-assisted analysis. See /stocks/DHR/earnings. Content is for research and education — not investment advice.

DHR

DANAHER CORP /DE/

Healthcare · Diagnostics & Research

$224.49Sep 25, 2026

AI confidence 70% · prior close shown (market closed)

Investment Snapshot

Strong evidence · 3 sources

Why it matters

DANAHER CORP /DE/ shows stable business momentum based on AlphaOS pipeline evidence, with mixed management execution.

Why it matters: Revenue +4% YoY in Q1 FY2026.

TrajectoryStable

ExecutionMixed

RiskMedium

1 signal not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

Revenue +4% YoY in Q1 FY2026
Stable Guidance

Pipeline evidence · 0d ago

DHR's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on DHR.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q1 2026

Full DHR earnings analysis

Reported figures for DANAHER CORP /DE/ — research only, not investment advice.

Revenue YoY: +3.7%
EPS YoY: +9.8%

Latest Intelligence

Updated September 28, 2026

What happened recently for DANAHER CORP /DE/ (DHR) — events, not interpretation.

Event: Reported Q1 2026 revenue +4% YoY.
Also: Last session September 25, 2026 at $224.49.
Source: Q1 2026 earnings

Research & analysis only — not investment advice.

Industry & ETF context

Industry blend 57

Primary industry Diagnostics & Research scores 57/100 (Early Recovery cycle, Strong momentum).

AlphaOS industries

Diagnostics & Research

Primary

Score 57Early RecoveryStrong momentum

Investment snapshot

DANAHER CORP /DE/

DHR's opportunity score

Upgrade to Premium

Analysis confidence: 70%

DHR's AI investment thesis

Upgrade to Premium for DHR's full multi-agent investment thesis.

Create free account

Free accounts see more of this; Premium sees all of it.

70% confidence

Intelligence layer

Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity

PricesFinancialsFilingsFiling insightsEarningsEarnings AITranscriptsTechnicalOpportunityResearch

→Management tone: neutral
→Filing signal: Potential insider selling

Strengthen intelligence

· Fetch earnings call transcript for CEO commentary

Prior close

$224.49

Market cap

$157.81B

Profitable

Yes

Revenue $5.95B

Net income

$1.03B

FY Sep 18, 2026

Analyst ratings

Loading Wall Street consensus…

Earnings intelligence

Full earnings center

Loading earnings intelligence…

Technical intelligence

Building technical intelligence snapshot — check back shortly.

Loading market context…

Price & volume

0 trading days

No price history. Sync market data to load charts.

Filing insights

Loading SEC filing intelligence…

Competitive landscape

Recent SEC filings

Filings tab

No filings ingested yet.

DANAHER CORP /DE/ (DHR)

Healthcare · Diagnostics & Research

Investment Snapshot above is the primary AlphaOS analysis for DANAHER CORP /DE/ — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:: Healthcare
Industry:: Diagnostics & Research
Market cap:: $157.81B
Revenue:: $5.95B

DHR earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow DANAHER CORP /DE/ through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Themes